Vedanta Biosciences, a subsidiary of PureTech Health, has enrolled its first patient in the Phase 1b/2 clinical study of VE416 in adults and adolescents with a history of peanut allergy, it was reported yesterday.
The product is the company's live biotherapeutic product candidate being developed for treatment of food allergies, including persistent peanut allergy.
The study is being conducted at MassGeneral Hospital for Children and will explore VE416 as a monotherapy, and in combination with an oral peanut immunotherapy, over the course of several months. The randomised, double-blind, placebo-controlled trial is scheduled to enrol up to 40 patients that are 12 years of age and older. The primary endpoints are safety of VE416 and amount of peanut protein tolerated during a double-blind, placebo-controlled food challenge following the treatment.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary